Eli Lilly is back in business with their experimental monoclonal antibody (mAb) product as U.S. demand for monoclonal antibody treatments spike during the Delta-variant has…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.